Longeveron will participate in the BIO International Convention, June 22-25, 2026, at the San Diego Convention Center and will present a company and laromestrocel (Lomecel-B) overview on 24 June at 2:15 pm PT in Theater 4.
Company representatives Stephen Willard, Dr Joshua Hare and Than Powell will host meetings with global pharmaceutical executives to explore partnerships for laromestrocel programs in hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty, which the company estimates address market opportunities of approximately $1 billion, $5+ billion, $1 billion and up to $4 billion, respectively.
According to the company, laromestrocel has delivered positive initial results across five clinical trials in three indications, and the company has completed enrollment in the Phase 2b ELPIS II trial for HLHS, with top-line data anticipated in August 2026.
The product is an allogeneic mesenchymal stem cell therapy isolated from the bone marrow of young healthy donors, and the company claims a 52-patent global intellectual property portfolio and five FDA designations spanning orphan drug, fast track, rare pediatric disease and RMAT statuses.
Longeveron plans to pursue strategic licensing partnerships to accelerate development and leverage larger organizations’ resources.
